Edgewise Therapeutics doses first subject in HCM drug trial [Yahoo! Finance]
Edgewise Therapeutics, Inc. (EWTX)
Company Research
Source: Yahoo! Finance
An oral, selective cardiac sarcomere modulator, EDG-7500 is claimed to slow down early contraction velocity and address the impaired cardiac relaxation linked to HCM. The multicentre, open-label trial will be conducted across up to 20 clinical sites in the US, enrolling up to 30 adult patients with obstructive HCM. It will assess EDG-7500's safety, tolerability, pharmacokinetics (PK) and pharmacodynamics in these patients. Trial subjects will receive a single oral dose of EDG-7500, with some potentially receiving multiple doses over a 28-day period in the study. The trial is structured in two parts, with Part A assessing single doses of the therapy and Part B focusing on multiple doses orally over 28 days. Edgewise expects to report data from the single-dose arm of the trial, alongside results from a Phase I trial in healthy volunteers, in the third quarter of this year. Plans are also in place to begin a 28-day trial in patients with obstructive and non-obstructive HCM i
Show less
Read more
Impact Snapshot
Event Time:
EWTX
Last Price
Price Change
Price Change%
Volume Shares
Max Up
Max Down
%
Volume Ratio
Performance Comparison
Updated
|
Event Day
Stock performance from the time of news release until the following 4pm ET market close
|
Last price at news event
|
Since Event
Multi-day stock performance from the time of the news release
|
|---|---|---|
|
EVENT DAY
Stock performance from the time of news release until the following 4pm ET market close
|
LAST
PRICE AT NEWS EVENT |
SINCE EVENT
Multi-day stock performance from the time of the news release
|
| Last Price | ||
| VWAP | ||
|
High:
|
Max Up |
High:
|
|
Low:
|
Max Down |
Low:
|
|
%
|
Post news range |
%
|
|
|
Price change |
|
|
|
Price Change Percentage |
|
|
|
S&P 500 (SPX) |
|
|
%
|
Volume ratio |
%
|
| Volume | ||
| Ticks | ||
|
|
Avg transaction size |
|
Don't Miss Out On The Next BIG Stock Move
Event day
Event Day Chart will not be displayed beyond 90-day period of the event
Performance since event
Time And Velocity Analysis
Be the first to know
Opt in for alerts from News Quantifed
Sign Up Today
Opt-in for
EWTX alerts
Learn More With NQ
Reading the Impact Report
Help Me Understand This Data
Help Me Understand This Data
How NQ Works
What is news-based trading?
And why is it so successful?
And why is it so successful?
Movers & Shakers
The biggest gainers and losers and WHY it moved
EWTX alerts
High impacting Edgewise Therapeutics, Inc. news events
Weekly update
A roundup of the hottest topics
EWTX
News
- Edgewise: Intriguing Drug Candidate, But Consider Selling After Recent Run [Seeking Alpha]Seeking Alpha
- Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024 [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics to Present at the RBC Capital Markets Global Healthcare Conference on May 15, 2024Business Wire
- Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business Highlights [Yahoo! Finance]Yahoo! Finance
- Edgewise Therapeutics Reports First Quarter 2024 Financial Results and Recent Business HighlightsBusiness Wire
EWTX
Earnings
- 5/9/24 - Beat
EWTX
Sec Filings
- 5/10/24 - Form 8-K
- 5/10/24 - Form S-3ASR
- 5/9/24 - Form S-8
- EWTX's page on the SEC website